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Abstract
Deletion of the short arm of chromosome 3 is one of the most frequent genetic alterations in many solid tumors including
nasopharyngeal carcinoma (NPC), suggesting the existence of one or more tumor suppressor genes (TSGs) within the
frequently deleted region. A putative TSG RBMS3 (RNA binding motif, single stranded interacting protein 3), located at 3p24-
p23, has been identified in our previous study. Here, we reported that downregulation of RBMS3 was detected in 3/3 NPC
cell lines and 13/15 (86.7%) primary NPC tissues. Functional studies using both overexpression and suppression systems
demonstrated that RBMS3 has a strong tumor suppressive role in NPC. The tumor suppressive mechanism of RBMS3 was
associated with its role in cell cycle arrest at the G1/S checkpoint by upregulating p53 and p21, downregulating cyclin E and
CDK2, and the subsequent inhibition of Rb-ser780. Further analysis demonstrated that RBMS3 had a pro-apoptotic role in a
mitochondrial-dependent manner via activation of caspase-9 and PARP. Finally, RBMS3 inhibited microvessel formation,
which may be mediated by down-regulation of MMP2 and b-catenin and inactivation of its downstream targets, including
cyclin-D1, c-Myc, MMP7, and MMP9. Taken together, our findings define a function for RBMS3 as an important tumor
suppressor gene in NPC.
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Introduction
Nasopharyngeal carcinoma (NPC) is a distinct and geograph-
ically important disease [1], which accounts for 80,000 new cases
and 50,000 deaths per year [2]. The majority (75–90%) of newly
diagnosed NPC patients have loco-regionally advanced disease,
commonly with cervical nodal metastases [3]. Currently, the
standard of care for these patients consists of concurrent chemo-
radiotherapy with cisplatin-based regimens, generally followed by
adjuvant chemotherapy. The cause for NPC development is
complex, including viral, genetic and environmental factors[4–6].
It is widely accepted that infection by the Epstein-Barr virus (EBV)
plays a vital role in the pathogenesis of NPC; however, the
molecular pathogenesis is also associated with the inactivation of
tumor suppressor genes (TSGs). To date, the exact cellular and
molecular mechanisms leading to NPC have not been systemat-
ically evaluated.
The 3p chromosomal region is frequently deleted in multiple
solid tumors [9], suggesting the existence of one or more TSGs
contributing to the risk of developing NPC. Through massive
expression profiling and epigenetic characterization, we and others
have identified several interesting 3p targets genes in human
cancers, including BLU [10], RBMS3 [11] and two closely located
3p22 genes, DLEC1 [12] and PLCD1 [13,14]. RBMS3, a gene
located at 3p24-p23, encodes an RNA-binding protein that
belongs to the c-Myc gene single-strand binding protein (MSSPs)
family [15]. The MSSP family members are single strand DNA-
binding proteins that cooperate with the Myc protein to regulate
DNA replication, gene transcription, cell cycle progression, and
induction of apoptosis. C-Myc is over-expressed in most cancers
and executes its diverse functions through transcriptional regula-
tion of its target genes [16]. Over-expression of c-Myc was also
found as a frequent genetic abnormality in NPC [17,18]. The
RBMS3 protein was isolated through its binding to an upstream
element of the alpha2 (I) collagen promoter [19]. The RBMS3
protein localizes in the cytoplasm, suggesting it may be involved in
a cytoplasmic function such as controlling RNA metabolism,
rather than transcription. Multiple alternatively spliced transcript
variants encoding various isoforms of RBMS3 have been found.
Although RBMS3 could be a potential cooperator of the Myc
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protein, its role in the pathogenesis of NPC remains unclear. In the
present study, the expression pattern of RBMS3 in primary NPCs
and NPC cell lines was investigated. The tumor suppressive effects
and corresponding mechanisms of RBMS3 were characterized.
Results
RBMS3 is Frequently Down-regulated in NPC
Quantitative real-time PCR (qRT-PCR) was performed to
evaluate the expression levels of RBMS3 in 15 pairs of primary
NPCs and their corresponding non-tumor samples. Down-
regulation of RBMS3 was detected in 13/15 (86.7%) NPC tissues
compared to their normal counterparts (Fig. 1A). Furthermore, the
box plot showed a highly significant difference in the mean
expression levels of RBMS3 between NPC tumors and non-tumor
samples (p,0.001; Fig. 1B). We next examined RBMS3 expression
in NPC cell lines. The result showed that RBMS3 was
downregulated in all three tested NPC cell lines (C666, CNE2
and SUNE1) compared to the immortalized nasopharyngeal (NP)
cell line, NP460 (Fig. 1C). The protein expression level of RBMS3
was also evaluated in 30 pairs of primary NPCs and non-tumor
samples by immunohistochemical staining (IHC). Moderate or
strong nuclear staining of RBMS3 was detected in 30 non-tumor
tissues, whereas no or weak nuclear staining of RBMS3 was
observed in 24/30 (80.0%) of NPC tumor tissues (Fig. 1D).
RBMS3 has Tumor Suppressive Ability
To investigate whether RBMS3 has tumor suppressive ability,
RBMS3 was stably transfected into 2 NPC cell lines (SUNE1 and
CNE2), and 4 clones (SUNE1-R4, SUNE1-R5, CNE2-R1 and
CNE2-R2) were selected for functional studies. Empty vector-
transfected cells were used as control (SUNE1-V1 and CNE2-V1).
Expression of RBMS3 in SUNE1-R4, SUNE1-R5, CNE2-R1 and
CNE2-R2 cells was confirmed by qPCR (Fig. 2A) and Western
blot analysis (Fig. 2B). Tumor suppressive function of RBMS3 was
studied by cell growth assay, foci formation assay, and tumor
xenograft experiment. Cell growth assay showed that the growth
rates were significantly decreased in SUNE1-R4, SUNE1-R5,
CNE2-R1 and CNE2-R2 cells (p,0.05, Student’s t-test) compared
to SUNE1-V1 cells and CNE2-V1 cells, respectively (Fig. 2B).
Focus formation assay showed that RBMS3 could significantly
inhibit foci formation (p,0.001, Student’s t-test) in SUNE1-R4,
SUNE1-R5, CNE2-R1 and CNE2-R2 cells compared to control
cells (Fig. 2C).
The tumor suppressive potential of RBMS3 was also evaluated
by xenograft tumor formation in athymic nude mice. Subcutane-
ous tumor formation was observed in all nude mice injected with
SUNE1-V1 (n= 10) and CNE2-V1 (n= 10) cells 28 days post-
injection. Xenograft tumor growth curve showed that tumors
induced by SUNE1-R4 and SUNE1-R5 cells grew significantly
slower than the SUNE1-V1 cells (p,0.05) (Fig. 2D). The average
volume of the tumors induced by SUNE1-R4
(630.006135.18 mm3) and SUNE1-R5 (864.006144.68 mm3)
cells were significantly smaller compared to the tumors induced
by SUNE1-V1 cells (1687.806270.37 mm3, p,0.05) (Fig. 2D).
Similarly, the average volume of the tumors induced by CNE2-R1
(501.98673.12 mm3) and CNE2-R2 (522.13674.19 mm3) were
significantly reduced compared to the tumors induced by CNE2-
V1 cells (770.466187.07 mm3, p,0.05) (Fig. 2D).
RBMS3 Arrests Cell Cycle at G1-S Checkpoint
To understand the tumor suppressive mechanism of RBMS3,
flow cytometry was performed to compare the DNA content
between the SUNE1-Vec and SUNE1-RBMS3 cells. The results
showed that the proportions of SUNE1-RBMS3 cells in the G1-
phase and S-phase were significantly increased and decreased,
respectively, in the SUNE1-RBMS3 cells (p,0.05) compared with
SUNE1-Vec cells, suggesting that RBMS3 was able to arrest cell
cycle at G1/S checkpoint (Fig. 3A). Western blot analysis found
that the G1/S checkpoint promoting factors (CDK2, cyclin E and
cyclin D1) and inhibiting factors (p53 and p21) were downregu-
lated and upregulated in RBMS3-tansfected NPC cells, respec-
tively, compared to control cells (Fig. 3B). Since CDK2 plays a
critical role in the inactivation of Rb, the level of the inactive form
(phosphorylated) of Rb was also compared between RBMS3-
transfected and vector tarnsfected NPC cells by western blotting.
The result showed that inactive form of Rb (Ser780) was reduced
in RBMS3-transfected cells compared to control cells. However,
the total amount of Rb protein did not change significantly
(Fig. 3B).
Ectopic Expression of RBMS3 Induces Apoptosis
To explore whether RBMS3 has a pro-apoptotic effect, the
apoptotic index was compared between SUNE1-Vec and SUNE1-
RBMS3 cells by TUNEL staining. Prior to straurosporine (STS)
treatment, TUNEL analysis revealed that the apoptotic index in
SUNE1-Vec cells (0.5%60.9%) was lower than SUNE1-RBMS3
cells (7.1%66.0%; p= 0.057). After STS treatment, the apoptotic
index in SUNE1-Vec (14.8%64.1%) was significantly lower than
that of SUNE1-RBMS3 (45.3%64.5%; p,0.05), confirming that
RBMS3 had a pro-apoptotic ability (Fig. 4A). To elucidate the
molecular basis of apoptosis, we examined the potential for pro-
apoptotic mitochondrial permeability transition by measuring the
loss of mitochondrial DYm using JC-1 dye. Red or orange
fluorescence indicates intact mitochondria, whereas green fluores-
cence indicates a collapse in mitochondrial DYm. The results
showed that the mitochondrial permeability and apoptotic index
in RBMS3-transfected cells were significantly higher than those of
control cells even prior to STS treatment (Fig. 4B). Western blot
analysis also indicated that the cleavage of caspase-9 and PARP
was dramatically increased in SUNE1-RBMS3, however, no
change was observed for caspase-8 (Fig. 4C).
RBMS3 Inhibits Angiogenesis
To study the potential effect of RBMS3 on angiogenensis, the
development of microvessel in tumor sections of mouse xenografts
was examined by IHC staining with a vascular endothelial cell
marker CD34. As shown in Fig. 5A, a robust angiogenic response,
as determined by high CD34 positivity, was observed in the empty
vector-induced tumors. Conversely, CD34-positive vessels were
rarely found within the RBMS3-induced tumors. The number of
vessels counted in RBMS3-induced and empty vector-induced
tumors was summarized in Table 1. Furthermore, the mRNA
expression level of VEGF was also compared between RBMS3-
transfected and vector-transfected NPC cells by qPCR analysis. As
shown in Fig. 5B, the expression of VEGF was dramatically
decreased in RBMS3-transfected NPC cells compared to control
cells. (p,0.05, Fig. 5B).
A recent study found that silencing b-catenin expression by
RNA interference could inhibit angiogenesis-related gene expres-
sion (e.g., MMP9, MMP2, and VEGF) in hepatocellular
carcinoma cells [20]. We next studied whether RBMS3 could
intercept the expression of b-catenin in NPC cells. As shown in
Fig. 5C and Fig. 5D, b-catenin from both whole cell extracts and
nuclear fractionation was downregulated in RBMS3-transfected
NPC cells compared to control cells. The downstream targets of b-
catenin including C-Myc, MMP7, MMP9, and MMP2 (the latter
two are angiogenesis-related proteins) were also detected in
RBMS3 in Nasopharyngeal Carcinoma
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RBMS3-transfected NPC cells. As expected, all the b-catenin
downstream targets including the two angiogenesis-related pro-
teins MMP9 and MMP2 were significantly downregulated in
RBMS3 transfected NPC cells, suggesting that RBMS3 has a
strong angiogenesis inhibiting role in NPC (Fig. 5E).
Figure 1. Downregulation of RBMS3 in nasopharyngeal carcinoma (NPC). (A) Expression of RBMS3 in 15 primary NPC cases was compared
using qPCR between tumor tissues (T) and their paired normal tissue (N). GAPDH was set as an internal control. (B) RBMS3 expression was normalized
by internal control GAPDH. Statistical analysis confirmed the qPCR results (p,0.001). (C) qPCR analysis of RBMS3 expression in three NPC cell lines
(C666, CNE2 and SUNE1). The fold changes of RBMS3 expression were compared with the immortalized NP cell line, NP460. (D) Immunohistochemical
detection of RBMS3 protein in NPC tissue samples and non-tumor nasopharyngeal tissues. Normal: strong positive staining for RBMS3 protein in
normal nasopharyngeal epitheliums (arrowhead). NPC1: weak positive staining for RBMS3 protein in NPC tissues (arrowhead). NPC2: negative staining
for RBMS3 protein in NPC tissues (arrowhead).
doi:10.1371/journal.pone.0044636.g001
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Figure 2. Tumor suppressor function of RBMS3 in NPC cells. Expression of RBMS3 in RBMS3-transfected SUNE1 (SUNE1-R4 and R5) and CNE2
cells (CNE2-R1 and R2) was confirmed by quantitative PCR (A) and Western blot (B). Empty vector-transfected cells (SUNE1-V1, CNE2-V1) were used as
control. (C) An MTT assay was used to compare cell growth rate between RBMS3- and empty vector-transfected NPC cells. The results found that cell
RBMS3 in Nasopharyngeal Carcinoma
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To further demonstrate the tumor-suppressive function of
RBMS3, RNAi was used to knockdown endogenous RBMS3
expression in NP460 cells. The silencing effect was confirmed by
both qPCR and western blotting (Fig. 6A). The function of RBMS3
in RBMS3 knockdown NP460 cells was studied by cell growth
assay, foci formation assay, and cell cycle analysis. The results
showed that knockdown of RBMS3 in NP460 cells could increase
cell growth rate (Fig. 6B), enhance foci formation ability (Fig. 6C),
and promote cell cycle (Fig. 6D) compared to control cells.
Moreover, we found that the expression of VEGF was significantly
upregulated in RBMS3 knockdown NP460 cells by qPCR analysis
(Fig. 6E), whereas b-catenin was upregulated and p53 was
downregulated in RBMS3 knockdown NP460 cells by western
blotting (Fig. 6F), as compared to control cells. These observations
further support that RBMS3 is an important tumor suppressor
with anti-proliferation and anti-angiogenesis abilities in NPC.
Discussion
The etiology of NPC is complex, and includes viral, genetic and
environmental factors [4–6]. The earliest and most common
genetic change observed in NPC patients maps to the short arm of
chromosome 3 where deletions are observed frequently. One
candidate tumor suppressor gene, RBMS3, which resides on
human chromosome 3p24-3p23, is widely expressed in the
embryo as well as in the adult organisms. In the present study,
downregulation of RBMS3 was frequently detected in NPCs at
both the mRNA and protein levels, suggesting that RBMS3 might
play a pivotal role in the NPC development and progression. The
observation that this protein localizes in the nuclear suggests that it
may be involved in a nuclear fuction such as controlling RNA
transcription. The tumor-suppressive function of RBMS3 was
characterized in two NPC cell lines (SUNE1 and CNE2). Both in
vitro (cell growth rate, colony formation in soft agar and foci
formation) and in vivo (tumor formation in nude mouse) assays
growth rate was significantly decreased in RBMS3-transfected SUNE1 and CNE2 cells (* p,0.05; ** p,0.001, Student’s t-test). Values were expressed
as mean 6 SD of three independent experiments. (D) Foci formation assay showed that the number of foci was significantly decreased in RBMS3-
transfected SUNE1 and CNE2 cells compared to the control cells, respectively (** p,0.001, Student’s t-test). The results were expressed as mean6 SD
of three independent experiments. (E) Representatives of tumor formation in nude mice. Tumors induced by SUNE1-V1 (left) and SUEN1-RBMS3
(right) were indicated by arrows, respectively. Excised tumors were shown in the bottom. Summary of tumor growth rates in nude mice induced by
RBMS3- and empty vector-transfected NPC cells. The average tumor volume was expressed as mean 6 SD in 10 inoculated sites for each group (*
p,0.05).
doi:10.1371/journal.pone.0044636.g002
Figure 3. RBMS3 arrests cell cycle at the G1/S checkpoint. (A) Representative and summary of DNA content detected by flow cytometry
showed that the percentage of cells in the S phase was lower while the percentage of cells in the G1 phase was higher in SUNE1-RBMS3 cells than
that in SUNE1-V1 cells. (* p,0.05, Student’s t-test). Values were expressed as mean 6 SD of three independent experiments. (B) Protein expressions
of cyclin D1, cyclin E, CDK2, p53, p21, Rb and Rb (Ser780) were compared between RBMS3- and empty vector-transfected NPC cells. b-actin was used
as a loading control.
doi:10.1371/journal.pone.0044636.g003
RBMS3 in Nasopharyngeal Carcinoma
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Figure 4. Ectopic expression of RBMS3 induces apoptosis. (A) Representative images of TUNEL staining. After STS treatment, more apoptotic
cells (green) were detected in SUNE1-RBMS3 cells compared to SUNE1-V1 cells (arrowhead). The apoptotic indexes of SUNE1-RBMS3 cells and SUNE1-
V1 cells (before and after STS treatment) were summarized in the right panel (*p,0.05). (B) This event was measured by loss of mitochondrial DYm
using JC-1 dye. Red or orange fluorescence indicates intact mitochondria, whereas green fluorescence indicated a collapse in mitochondrial DYm.
Prior to STS treatment the SUNE1-RBMS3 cells reveal a significant DYm loss (green fluorescence,6400) and higher apoptotic index compared to
SUNE1-V1 cells (red/orange fluorescence; left panel) (*p,0.05). (C) The cleavages of caspase-9, caspase-8, and PARP were compared between RBMS3-
transfected and empty vector-transfected SUNE1 cells. b-actin was used as loading control.
doi:10.1371/journal.pone.0044636.g004
RBMS3 in Nasopharyngeal Carcinoma
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Figure 5. RBMS3 inhibits angiogenesis. (A) The tumor sections were stained for the endothelial cell marker CD34 (6200). The RBMS3-induced
tumors had a lower degree of microvessel densities compared to empty vector-induced tumors. (B) Expression of VEGF in RBMS3-transfected SUNE1
RBMS3 in Nasopharyngeal Carcinoma
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demonstrated that RBMS3 had a strong tumor suppressive
potential in NPC cells.
Molecular analysis found that the tumor-suppressive effect of
RBMS3 was closely associated with its role in cell cycle arrest at
G1/S checkpoint via upregulation of p53 and p21, and
downregulation of cyclin D1, cyclin E/CDK2 and Rb-ser780.
The increased expression of p53, which is a DNA-binding protein
and functions as a tumor suppressor, can induce the expression of
p21. p21 has a pivotal role in the G1/S transition through
inhibiting the cyclin E/CDK2 complex [21]. Activation of the
cyclin E/CDK2 complex can destruct Rb-E2F binding, which
contributes to the reduction of phosphorylation form of Rb, and
finally activates the transcription of genes necessary for S-phase
entry and cell cycle progression [22,23]. These findings indicate
that RBMS3 could be necessary for an orderly G1/S transition in
NPC cells.
Another data supporting that RBMS3 is a tumor suppressor in
NPC was its role in inducing apoptosis. Notably, the apoptotic
index between RBMS3 transfected NPC cells and control cells
showed significant difference after STS treatment, indicating a
unique mechanism underlying the strong pro-apoptotic effect of
RBMS3 in NPC cancer cells. It has been reported that RBMS3
increased the expression of Prx1 transcription factor [19], which is
a tumor suppressor in esophageal squamous cell carcinoma [24].
Prx1, as a novel interaction partner for the lifespan regulator
protein p66Shc, binds to the N-terminal domain of p66Shc
[25,26], and subsequently induces changes in the permeability
transition of mitochondrial membranes and results in the release of
cytochrome C and apoptosome activation [27,28]. Interestingly,
our results also found that the pro-apoptotic role of RBMS3 was
mediated through the intrinsic mitochondrial pathway, as caspase-
9 and mitochondrial permeability, but not caspase-8, was
increased. However, whether RBMS3 could induce the expression
of Prx1 and lead to the activation of a similar apoptotic pathway
need to be further investigated.
Whether or not the growth of vessels occurs in a tissue depends
on the equilibrium between the relative amounts of molecules that
induce and inhibit angiogenesis [29]. A growing body of evidence
illustrates that the inactivation of TSG and activation of oncogenes
play an important role in this phenotypic switch. For instance,
oncogenic stimuli such as ras, v-src and c-jun [30–33] and
inactivation of p53, VHL, and RB2/P130 results in an increased
VEGF production [30,34,35]. Our data demonstrate that RBMS3
can modulate the angiogeneic balance and inhibit the microvessel
formation potentially through increasing the expression of p53 and
decreasing the expression of MMP9 and MMP2 [36].
b-catenin is maintained at low levels in quiescent cells by
interaction with protein kinases, such as adenomatous polyposis
coli, casein kinase 1, and glycogen synthase kinase 3 [37]. The
aberrant cytoplasmic accumulation of b-catenin induces Tcf/Lef-
mediated transcriptional activity, and enhances the invasion and
migration of oral squamous cell carcinoma [38]. The translocation
of b-catenin into the nucleus can initiate carcinogenesis when Wnt
is present [39]. b-catenin levels in nucleus are increased in 92% of
NPC tumors, making b-catenin an important component in NPC
development [40,41]. Our data showed that b-catenin from both
whole cell extracts and nuclear fractionation was significantly
downregulated in RBMS3 transfected NPC cells compared to
control cells, suggesting that RBMS3 could inhibit the nuclear
translocation of b-catenin in NPC cells. The inhibition of b-
catenin nuclear translocation in RBMS3-expressing cells was
further confirmed by detecting downregulation of its targets
including c-Myc, MMP7, MMP9 and MMP2. Overexpression of
c-Myc has been detected in about 90% of NPCs which was
associated with poor survival rate in NPC patients [42,43]. MMP7
is one of the well-known targets of b-catenin. It has been reported
that MMP7 plays an essential role in cancer invasion and
metastases [44,45]. In this study, MMP7 expression could be
effectively downregulated when RBMS3 was introduced into NPC
cells.
Moreover, our group recently revealed that RBMS3 could
directly bind to the promoter region of c-Myc [46], suggesting that
RBMS3 also possesses the DNA binding activity. Based on our
findings, we hypothesize that RBMS3 may regulate certain key
proteins involved in cell cycle, apoptosis and angiogenesis. The
potential molecular mechanisms underlying the RBMS3-mediated
tumor suppression in NPC are summarized in Fig. 7. In
conclusion, our data provide a foundation to explore the role of
RBMS3 in the NPC pathogenesis. More comprehensive under-
standing of the tumor suppressive mechanisms of RBMS3 in NPC
would provide much more effective therapeutic strategy for the
management of NPC patients.
Materials and Methods
Ethics Statement
Tumor specimens used in this study were approved by the
Committees for Ethical Review of Research involving Human
Subjects at University of Hong Kong. Written Informed consent
was obtained from the patients involved. Animal operation was
carried out according to the protocols approved by the Committee
on the Use of Live Animals in Teaching and Research
(CULATRA). Lisence which could conduct live animal experi-
ments was approved by Hong Kong Department of Health
(lisence no. (09–770) in DH/HA&P/8/2/3 Pt.17).
Cell Lines and Primary Tumor Specimens
EBV-positive NPC cell line C666 was derived from NPC tissue
harbored latent EBV infection [47,48], while EBV-negative NPC
cell lines CNE2 and SUNE1 were derived from poorly differen-
and CNE2 cells was confirmed by qPCR. Empty vector-transfected cells were used as control. (C) Representative IF images showed that b-catenin was
mainly localized in the nucleus of SUNE1-RBMS3 cells, whereas it was mainly localized in cell membrane and cytoplasm in SUNE1-V1 cells. (D) Western
blot analysis of b-catenin from whole cell, nuclear and cytosolic extract was compared between in RBMS3- and empty vector-transfected SUNE1 and
CNE2 cells. b-actin and PCNA were used as loading control. (E)Western blot analysis of c-Myc, MMP7, MMP9 and MMP2 was compared between
RBMS3- and empty vector-transfected SUNE1 and CNE2 cells. b-actin was used as loading control.
doi:10.1371/journal.pone.0044636.g005
Table 1. Quantitation of microvessels formed in empty
vector and RBMS3-transfected NPC cells induced mouse
tumor xenografts (n = 10 tumors/group).
Cell lines
aVessel count P
Vec RBMS3
SUNE1 78.6616.9 23.468.5 ,0.001**
CNE2 87.9627.1 29.666.7 ,0.001**
aValues represent mean6standard error.
**Statistically significant as compared to control cells.
doi:10.1371/journal.pone.0044636.t001
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Figure 6. RBMS3-silenced NP460 cell showed malignant features. (A) siRNA against RBMS3 effectively reduced the mRNA and protein
expression of RBMS3 in NP460 cells compared to siScramble-transfected cells. (B) An MTT assay was used to compare cell growth rates between
RBMS3 in Nasopharyngeal Carcinoma
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tiated NPC [49]. NP460 is an immortalized nasopharyngeal
epithelium cell line [50]. Three NPC cell lines (C666, SUNE1,
CNE2) and one immortalized nasopharyngeal epithelial cell lines
(NP460) were kindly provided by Professor Tsao (Department of
Anatomy, The University of Hong Kong). CNE2, SUNE1 and
C666 were cultured in RPMI-1640 medium supplemented with
10% fetal bovine serum. NP460 cells were cultured in defined
keratinocyte serum-free medium.
The primary NPC tumor tissues and their paired nontumorous
tissues from 15 confirmed NPC patients (Age: 44–77 years;
Female: n= 4; Male: n = 11) were collected immediately after
surgical resection from the Queen Mary Hospital in Hong Kong.
Samples used in this study were collected following methods
approved by the Committee for Ethical Review of Research
involving Human Subjects at the University of Hong Kong.
Establishment of RBMS3 Expressing Cell Lines
The OmicsLink-RBMS3 was purchased from GeneCopoeia
Inc. (Germantown, MD) and sub-cloned into pcDNA3.1 (+)
(Invitrogen, Carlsbad, CA) according to the manufacture’s
protocol. RBMS3 was then stably transfected into the NPC cell
lines SUNE1 and CNE2 using LipofectamineTM 2000 (Invitro-
gen, Carlsbad, CA). Blank vector pcDNA3.1 (+) transfected cells
(SUNE1-V1 and CNE2-V1) were used as controls.
RNA Extraction, Reverse Transcription and PCR
Total RNA from cultured cells and tumor tissues were extracted
using Trizol (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Reverse transcription of total RNA
was performed using SuperScript III kit (Invitrogen, Carlsbad,
CA). The expression of RBMS3 was determined by RT-PCR at
RNA level using the appropriate primer set (RBMS3-F: 59-
ACAAGAGCAAGACCCAACA- AA-39; RBMS3-R: 59-
TGTCCAAAGGGTTTCAGCATA-39). Images were processed
and analyzed with ImageJ software (Wayne Rashband, Nationlal
Institute of Health, Bethesda, MD). Quantitative data were
exported and RBMS3 expression was normalized using GAPDH
as a control.
Quantitative Real-time PCR (qPCR)
qPCR was performed using the SYBR Green Supermix and the
ABI7900HT Fast Real-Time PCR system (Applied Biosystems,
Foster City, CA). RBMS3 specific primers (RBMS3-F: 59-
ACAAGAGCAAGACCCAACAAA-39; RBMS3-R: 59-
siRBMS3- and siScramble-transfected NP460 cells (* p,0.05; ** p,0.001, Student’s t-test). Values were expressed as mean6 SD of three independent
experiments. (C) Foci formation assay showed that the number of foci was significantly increased in siRBMS3-transfected NP460 cells compared to
control cells (* p,0.05, Student’s t-test). The results were expressed as mean 6 SD of three independent experiments. (D) Representative and
summary of DNA content detected by flow cytometry showed that the percentage of cells in the S phase was higher while the percentage of cells in
the G1 phase was lower in siRBMS3-transfected NP460 cells than that in control cells. (* p,0.05, Student’s t-test). (E) Expression of VEGF in siRBMS3-
and siScramble-transfected NP460 cells was confirmed by qPCR. (* p,0.05, Student’s t-test). The results were expressed as mean 6 SD of three
independent experiments. (F) b-catenin was significantly up-regulated while p53 was significantly down-regulated in siRBMS3-transfected NP460
cells compared to control cells by Western blot analysis. b-actin was used as a loading control.
doi:10.1371/journal.pone.0044636.g006
Figure 7. A schematic diagram showing the role of RBMS3 in malignant transformation of nasopharyngeal carcinoma cell. Activation
R, inhibition R.
doi:10.1371/journal.pone.0044636.g007
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TGTCCAAAGGGTTTCAGCATA-39) were bought from Gen-
eCopoeia Inc. (Germantown, MD). The 18s RNA was used as
internal control. The assay was performed in triplicate and values
were normalized using the internal control. PCR was performed
for 40 cycles at 95uC for 10sec, 60uC for 20sec and 72uC for 15sec.
PCR products were subjected to a dissociation curve analysis using
the light cycler system to exclude amplification of nonspecific
products. Quantitation of the PCR data was processed using the
DCT method as described previously [51].
Tumor-suppressive Function of RBMS3
To test the tumor-suppressive function of RBMS3, stable
RBMS3-expressing clones (SUNE1-R4, SUNE1-R5, CNE2-R1
and CNE2-R2) were selected for further study. Empty vector
transfected NPC cells (SUNE1-V1 and CNE2-V1) were used as
control. Cell proliferation assay and foci formation assay were
carried out as described previously [13]. The in vivo tumor
suppression ability of RBMS3 was investigated using a tumor
xenograft experiment. Approximately 26106 RBMS3-expressing
cells and control cells were injected subcutaneously (s.c.) into the
right and left hind legs of 4-week-old nude mice (n = 10 for each
group), respectively. Tumor formation in nude mice was
monitored over a 4-week period. The tumor volume was
calculated by the formula V= 0.56L6W2. Following sacrifice,
tumors were excised, fixed in 10% formalin and embedded in
paraffin block for IHC study.
Small Interfering RNA Transfection
RBMS3 expression was silenced by double-stranded siRNA of
targeting of RBMS3 (sense 59-CCAACCGCAUGAUUCCACAtt-
39; antisense 59-UGUGGAAUCAUGC- GGUUGGtt-39) and
scramble siRNA, which were obtained from Ambion’s prede-
signed siRNA database (Ambion, Inc., Austin, TX). NP460 cells
were transfected with siRNA using LipofectamineTM 2000
(Invitrogen, Carlsbad, CA) according to the manufacture’s
instruction. Forty-eight hours after transfection, the effect of
gene-silencing was measured by qPCR and Western blot analysis.
Scramble siRNA was used as a negative control.
Cell Cycle Analysis
RBMS3 and vector-transfected SUNE1 cells (16106) were
cultured in RPMI medium containing 10% fetal bovine serum
(FBS), while si-RBMS3 and si-scramble transfected NP460 cells
were cultured in defined keratinocyte serum-free medium. Serum
was withdrawn from culture medium when cells were 70%
confluent. After 72 h, 10% FBS was added in the medium for an
additional 12 h. Cells were fixed in 70% ethanol, stained with
propidium iodide, and DNA content was analyzed using Cytomics
FC (Beckman Coulter).
Immunohistochemistry (IHC)
Tumor sections (5 mm thick) from primary NPCs or mouse
xenografts were used for immunohistochemical analysis. Briefly,
paraffin-embedded sections were deparaffinized, blocked with goat
serum, followed by incubation with mouse anti- RBMS3 (1:100) or
anti-CD34 (1:100) overnight at 4uC. After incubation with
horseradish peroxidase linked secondary antibody for 30 min,
the sections were counterstained with Mayer’s hematoxylin. For
RBMS3 staining, the scores were determined by the intensity of
staining: positive staining (moderate and strong nuclear staining)
and downregulation (absent and weak staining).
Microvessel Density Analysis
Tumor xenograft sections were stained for CD34, and four
random medium-power fields (6200) were photographed for each
tumor. Vessels were counted by a blinded observer using standard
criteria [52].
Immunofluorescence (IF)
RBMS3 and vector-transfected SUNE1 cells were grown on
gelatin-coated cover slips, fixed with 4% paraformaldehyde,
permeabilized in PBS, which contain 0.1% Triton-X 100, and
blocked with 1% bovine serum albumin. The cells were then
treated with antibodies targeting b-catenin (Cell Signaling
Technology, Danvers, MA) at 4uC overnight. After washing with
PBS, cells were incubated with FITC-conjugated anti-mouse
secondary antibody and Texas red–conjugated anti-rabbit sec-
ondary antibody at room temperature for 1 hour. Antifade 49, 6-
diamidino-2-phenylindole (DAPI) solution was added, and images
were captured.
Transferase-mediated dUTP Nick-end Labeling (TUNEL)
Assay
RBMS3 and vector-transfected SUNE1 cells were treated with
straurosporine (STS; 1 mM) for 2 hours. Morphological changes in
the nuclear chromatin undergoing apoptosis were detected by
terminal deoxynucleotidyl TUNEL assay according to the
manufacturer’s protocol (Roche, Mannheim, Germany). Images
were captured using a Leica DMRA fluorescence microscope
(Rueil-Malmaison, France). Triplicate independent experiments
were performed.
Mitochondrial Membrane Potential Assay
A MitoPTTM JC-1 Detection kit (Immunochemistry Technol-
ogies, Bloomington, MN) was used to detect the loss of
mitochondrial membrane potential (DYm). Briefly, cells were
cultured on cover slips until 80% confluence was attained in a 6-
well plate. Before and after STS treatment, cells were washed
twice with phosphate-buffered saline (PBS) and incubated with the
DYm-sensitive dyes JC-1 at 37uC for 15 min, and a fluorescence
microscope was used to capture the image with a Leica DMRA.
Cell Fractionation
Separation of nuclear and cytosolic fractions was performed
using the NucBuster Protein Extraction kit (Novagen Inc,
Madison, WI) according to the manufacturer’s instructions.
Western Blot Analysis
Western blot was performed according to the standard protocol
with antibodies for cyclin D1, b-actin, E-cadherin, MMP7, and
MMP9 (Santa Cruz Biotechnology, Santa Cruz, CA); p21, p27,
cyclin E, p53 caspase-8, and caspase-9, (Cell Signaling Technol-
ogy, Danvers, MA); and RBMS3 (Abnova, Taiwan).
Statistical Analysis
Statistical analysis was performed with the SPSS standard
version 13.0. Results expressed as mean 6 SD were analyzed
using Student’s t test. Differences were considered significant when
P value was ,0.05.
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